SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics, has completed a strategic investment in OrangeTwist, a U.S.-based medspa chain, signaling its official entry into the U.S. market. The partnership, announced late last month, combines SBC's network of 258 affiliated clinics and management of over six million patient visits annually with OrangeTwist's 24 locations across six U.S. states. OrangeTwist specializes in non-invasive aesthetic treatments such as injectables, energy-based therapies, and regenerative procedures, which are in high demand both domestically and internationally.
The collaboration aims to pursue joint operations, leveraging synergies in the U.S. and Asia. OrangeTwist's advanced management system, integrating procurement, clinical workflows, and real-time KPI tracking, aligns with SBC's operational expertise. Healthcare-focused private equity firm Hildred Capital and Athyrium Capital are longstanding institutional shareholders in OrangeTwist, providing additional financial backing.
This deal is significant as it marks SBC's official foray into the U.S. market, which is projected to grow from $34 billion to $48 billion by 2030, driven by demand for non-surgical treatments. The aging U.S. population further fuels demand for procedures with minimal risk and downtime. SBC plans to provide funding and professional know-how to enhance OrangeTwist's offerings, support faster expansion into new locations, and address "white space" markets—cities with high demand but few competitors.
Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga in an interview that the company plans more strategic investments in the U.S. "As part of SBC's global expansion, we are working hard to find local partnerships rather than copying and pasting what we did in Japan," Rodgers said. SBC seeks partners that align with its mission, hold leadership positions, and can scale, similar to OrangeTwist. Beyond running clinics together, the companies plan to jointly develop branded products and sell existing products in each other's spas.
The longevity industry also presents growth opportunities. With 4.1 million people turning 65 each year in the U.S. alone, the global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030, according to Gabelli Research. North America accounts for about 30% of the market, while Asia sees robust growth driven by beauty-conscious consumers and an aging population. SBC is positioned to offer AI-powered diagnostics, GLP-1 weight-loss drugs, and regenerative therapies, leveraging its infrastructure and track record in high-quality, cost-efficient aesthetics and wellness services.
Beyond the U.S., SBC is expanding in Japan and Southeast Asia, replicating its proven business model. The company's strategy rests on three tenets: partnering with high-performing regional operators, deploying expertise to drive efficiencies, and securing first-mover advantages. Non-invasive cosmetic treatments are popular in Asian markets due to preferences for natural-looking results and minimal recovery time. By standardizing services, SBC ensures consistent quality across Japan, Thailand, and Singapore, aiming to become the region's leading provider of aesthetic beauty services.
SBC Medical's partnership model, demonstrated through OrangeTwist, is designed for global replication. By sharing its successful approach with local providers, the company aims to build a trusted global brand. To learn more about SBC Medical, click here.
This content was originally published on Benzinga. Read further disclosures here.
